Delivering impact

Dan has extensive pharmaceutical leadership experience in the advancement and commercialization of novel medicines across geographic regions and in multiple therapeutic areas including neuroscience, oncology, and orphan diseases. He served as President of Jazz Pharmaceuticals (Nasdaq: JAZZ) from January 2018 until September 2023, and also as its Chief Operating Officer from January 2018 until May 2021 and from November 2022 until September 2023. At Jazz, Dan played an instrumental role in doubling the company’s product revenues since 2018, expanding its research and development pipeline and executing significant corporate development transactions. Prior to Jazz, he served as the President and Chief Executive Officer of Sunesis Pharmaceuticals from 2003 to 2017. There, he led the evolution of Sunesis from its early-stage chemistry platform to a multi-asset development portfolio. Earlier in his career, he served as Senior Vice President of Sales and Marketing at ALZA Corporation, contributing to its impressive growth leading up to its acquisition by Johnson & Johnson. Dan is also a member of the Board of Directors at Corcept Therapeutics (Nasdaq: CORT) and Chairman of the Board of Cerus Corporation (Nasdaq: CERS). He earned a B.A. from Yale University and an M.B.A. from Stanford University.

Alan has over 35 years of experience in drug discovery and development in both the pharmaceutical and biotechnology sectors. His previous roles include serving as Acting CSO at Bicycle Therapeutics, as Chief Operating Officer and Executive Vice President of R&D at Trident Pharmaceuticals, and as Chief Executive Officer of Xenovium Limited. Alan formerly led preclinical development for Neurology at GSK before relocating to Philadelphia as VP and Discovery Performance Unit Head at GSK where he established and led inflammation drug discovery. He also previously served as Head of Drug Metabolism and in vivo Pharmacology at Merck & Co’s Neuroscience Research Centre. Alan holds a Bachelor of Science in chemistry from the University of Southampton, a Ph.D. in drug metabolism from the University of Hertfordshire and an M.B.A. from the Open Business School. He has over 50 peer-reviewed scientific publications.

Alison is a seasoned healthcare finance executive with extensive transactional and operational experience. She formerly held a number of senior finance roles at GlaxoSmithKline, including as Chief of Staff to the Chief Finance Officer, where she was responsible for transforming GSK’s reporting processes as well as leading local completions globally of Novartis transaction. Alison also served as CFO of GSK’s drug discovery group, where she established the Tres Cantos Open Lab and Catalyst Science Park at GSK’s UK R&D site. Prior to working for GSK, Alison led the UK M&A life sciences sector group at Deloitte London. Alison holds a Ph.D. in chemistry and physical chemistry from the University of Wales, Cardiff.

Nick is leading the development of NodThera’s drug candidates through pre-IND testing. Prior to joining NodThera, he spent over 21 years at Pfizer in the UK and US, where he led successful drug development projects across a variety of therapeutic areas, including allergy, respiratory, inflammation and rare disease. Under his leadership, these projects progressed through early preclinical experimentation and candidate selection to initial clinical studies in volunteers and Phase 2a and Phase 2b studies in patients. Nick received his Bachelor of Science in pharmacology from the University of Portsmouth and his Ph.D. in anatomical neuropharmacology from the University of Oxford.

Dr. Jyothis George MBBS, PhD, FRCP, FACE is Chief Medical Officer at NodThera, where he leads the clinical development of the company’s NLRP3 inflammasome inhibitor portfolio. He joined NodThera from Amgen in 2025, where he was Global Medical Vice President for Obesity and Related Conditions, helping shape strategy for the company’s lead asset in obesity and related conditions, MariTide. He was previously Corporate Vice President for Clinical, Medical and Regulatory at Novo Nordisk , where he contributed to the development, approval and launch of multiple therapies including semaglutide (Wegovy^® and Rybelsus^®). Prior to that, he was head of global clinical development and medical affairs  at Boehringer Ingelheim accountable for two blockbuster cardiometabolic assets – empagliflozin (Jardiance^®) and linagliptin (Trajenta^®). Jyothis holds an M.B.B.S. from St. John’s Medical College, in Bangalore India, a Ph.D. in Neuroendocrinology from the University of Edinburgh, and is board certified in Internal Medicine, Endocrinology and Diabetes (UK). He is a Fellow of the Royal College of Physicians (Edinburgh) and the American College of Endocrinology and has authored more than 100 peer-reviewed publications with more than 12500 citations.